Introduction
The principal therapeutic strategies for patients with advanced non-small-cell lung cancer (NSCLC) include combinations of cytotoxic chemotherapy and targeted biologic therapies, such as bevacizumab and erlotinib (NCCN, 2008) . Despite the achievement of objective responses, the available treatments are associated with significant limitations in safety and efficacy (Schiller et al., 2002; NCCN, 2008) . This article reviews the clinical limitations of currently recommended therapies for patients with advanced NSCLC and discusses novel compounds in development that have shown promise for meeting the unmet medical needs in this disorder.
Current treatment recommendations for advanced disease
First-line treatment of recurrent and metastatic NSCLC The National Comprehensive Cancer Network (NCCN) has developed guidelines for the first-line treatment of patients with recurrent and metastatic NSCLC (Figure 1 ) (NCCN, 2008) . These guidelines recommend the use of chemotherapy in patients who have Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2. As the role of chemotherapy in the treatment of patients with advanced NSCLC (PS 3 or 4) is supportive and palliative at best, the routine use of chemotherapy is not recommended. As yet, there is no evidence that one platinum-based regimen is superior to another in terms of efficacy (Schiller et al., 2002) ; however, recent results from a randomized phase III trial suggest that pemetrexed/cisplatin may provide improved overall survival (OS) when compared with gemcitabine/cisplatin in patients with nonsquamous histology (Scagliotti et al., 2008a) . In addition, there are differences among the various platinum-based regimens with respect to safety profiles, convenience and cost, which should be considered when selecting the most appropriate treatment (NCCN, 2008) .
Bevacizumab is a recombinant humanized monoclonal antibody that binds and sequesters vascular endothelial growth factor (VEGF), a potent mediator of angiogenesis. It is the first antiangiogenic agent approved for the treatment of patients with NSCLC and can be combined with standard doublet chemotherapy for the first-line treatment of patients who have a PS of 0-1, nonsquamous histology, absence of brain metastases and hemoptysis, and no therapeutic anticoagulation. The benefit of adding bevacizumab to standard chemotherapy regimens has been shown in several trials; however, it has shown only modest improvement in time to progression (Johnson et al., 2004) and OS (Sandler et al., 2006) . For patients with a PS of 0-1 who do not meet the eligibility criteria for bevacizumab, a platinum-based chemotherapy regimen alone is recommended (NCCN, 2008) .
Advances in the knowledge of molecular underpinnings of tumorigenesis have led to the development of anticancer agents targeted against specific signaling molecules that contribute to tumor growth and progression. Such agents include those targeting the EGF receptor (EGFR; also known as HER or ErbB1) superfamily of cell-surface receptors that include EGFR, HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) (Bazley and Gullick, 2005) . EGFR is expressed in approximately >60% of metastatic NSCLCs and correlates with poor prognosis (Sharma et al., 2007) . Currently, the available methods for targeting EGFR include the use of monoclonal antibodies directed at the extracellular domain of EGFR or small molecules that inhibit the intracellular tyrosine kinase (TK) domain.
Cetuximab is a monoclonal antibody directed against EGFR. Recent results from the phase III FLEX trial showed that cetuximab added to chemotherapy (vinorelbine/cisplatin) modestly improved OS (11.3 vs 10.1 months; P ¼ 0.04) in chemotherapy-naive patients with advanced or recurrent NSCLC who had a PS of 0-2 and tumors that expressed EGFR (as detected by immunohistochemistry) (Pirker et al., 2008 is now recommended by the NCCN in combination with vinorelbine/cisplatin for patients with advanced or recurrent NSCLC who meet the cetuximab eligibility criteria (PS 0-2, EGFR expression as detected by immunohistochemistry (X1 positive tumor cell), aged X18 years, no brain metastases and no earlier chemotherapy or EGFR-targeted treatment) (Figure 1 ).
Second-and third-line treatment for progressive NSCLC The NCCN guidelines for the second-and third-line treatment of progressive disease are shown in Figure 2 ( NCCN, 2008) . For patients with a PS of 0-2 who have experienced disease progression during or after first-line therapy, single-agent regimens of either docetaxel or pemetrexed are among the recommended treatment options. Median OS produced with these agents is approximately 8 months (NCCN, 2008) . Erlotinib and gefitinib are reversible inhibitors of the EGFR TK domain, which is responsible for triggering the downstream signaling pathways of EGFR. These TK inhibitors (TKIs) were the first EGFR-targeted agents to be approved for the second-or third-line treatment of patients with advanced NSCLC after the failure of standard chemotherapy. Early clinical data showed that approximately 10% of patients with NSCLC responded to gefitinib or erlotinib (Shepherd et al., 2005; Thatcher et al., 2005) . However, gefitinib has been withdrawn from the United States and European markets after failing to show an OS benefit compared with placebo in a phase III study (Thatcher et al., 2005) . In contrast, erlotinib has shown superior progression-free survival (PFS) and OS compared with placebo with minimal toxicity in patients with advanced NSCLC who had received earlier chemotherapy (Shepherd et al., 2005) . Certain clinical subpopulations (never-smokers, women, East Asians and patients with adenocarcinomas with bronchioloalveolar histology) have been shown to be particularly responsive to treatment with EGFR TKIs (Shepherd et al., 2005; Thatcher et al., 2005) . In addition, molecular analysis showed that, in most instances, responders harbored specific mutations in the gene that encodes EGFR (Shepherd et al., 2005; Thatcher et al., 2005; Hirsch et al., 2007) . The NCCN also recommends single-agent erlotinib as a treatment option for patients with a PS of 0-2 who progressed during or after first-and/or second-line cytotoxic chemotherapy (Figure 2) (NCCN, 2008) .
Currently, no adequate treatment options exist for patients who have experienced erlotinib or gefitinib failure. For patients with a PS of 0-2 who experience the failure of third-line treatment, the NCCN recommends best supportive care or enrollment in a clinical trial. Patients with a PS of 3 or 4 and progressive disease during any stage of treatment should receive best supportive care only (NCCN, 2008) .
Factors influencing choice of treatment A patient's comorbidities or toxicities from previous treatments must be taken into account when selecting the best treatment regimen. For example, in patients with NSCLC and renal impairment, pemetrexed, which is eliminated by renal excretion (Mita et al., 2006) , may be avoided in favor of other drugs, such as erlotinib and docetaxel, which are metabolized by the liver and are minimally excreted by the kidneys (Gridelli et al., 2007; Stinchcombe and Socinski, 2008) . On the other hand, docetaxel may be avoided in favor of pemetrexed or erlotinib in patients with diabetic neuropathy or residual neuropathy from first-line therapy, as docetaxel has a higher rate of sensory neuropathy than do the other two agents (Hanna et al., 2004; Stinchcombe and . In patients with uncontrolled pleural effusions or ascites, methotrexate is contraindicated. Pemetrexed, which has a chemical structure similar to that of methotrexate, should also be avoided in these patients (Brandes et al., 2006; Stinchcombe and Socinski, 2008) .
Another factor that may influence the choice of therapies is the patient's risk for febrile neutropenia, a serious and potentially life-threatening complication of chemotherapy. Both patient-and regimen-specific risk factors have been identified for developing febrile neutropenia. Patient-specific risk factors include poor PS and advanced age (X70 years) (Crawford et al., 2004) . Erlotinib and pemetrexed have been associated with low rates of febrile neutropenia; therefore, these agents may be preferred for patients with risk factors associated with this toxicity (Stinchcombe and Socinski, 2008) . The patient's smoking history may also be a factor that can influence treatment decisions. The EGFR inhibitor erlotinib is most effective in neversmokers; therefore, erlotinib may be the preferred agent for such patients (Clark et al., 2006; Stinchcombe and Socinski, 2008) .
Recent results from a randomized phase III trial suggest that histology may be an important factor to consider when choosing a first-line chemotherapeutic regimen. A noninferiority trial of 1745 patients with advanced NSCLC showed that those with nonsquamous cell histology had improved OS with cisplatin plus pemetrexed versus cisplatin/gemcitabine (adenocarcinoma (n ¼ 847): 12.6 vs 10.9 months; hazard ratio (HR) ¼ 0.84; P ¼ 0.03; large cell (n ¼ 153): 10.4 vs 6.7 months; HR ¼ 0.67; P ¼ 0.03; nonsquamous (n ¼ 1000): 11.8 vs 10.4 months; HR ¼ 0.81; P ¼ 0.005) (Scagliotti et al., 2008a) . In contrast, OS for patients with squamous histology (n ¼ 473) was better in the cisplatin/gemcitabine arm (10.8 vs 9.4 months; HR ¼ 1.23; P ¼ 0.05). Overall, the cisplatin/pemetrexed regimen had significantly lower rates of grade 3/4 cytopenias (Pp0.001), febrile neutropenia (P ¼ 0.002) and alopecia (Po0.001). Treatment-related deaths were similar for both regimens. Thus, for patients with a nonsquamous histology, pemetrexed/cisplatin may be the preferred chemotherapeutic regimen.
Patient's preference should also be taken into consideration when making treatment decisions. In a survey to assess patient's preferences, 73% of respondents reported that if given the option of choosing among various chemotherapy regimens with equivalent efficacy outcomes, they would choose a chemotherapy regimen by its side effect profile (Dubey et al., 2005) . In addition, some patients may prefer oral agents, such as erlotinib, over injectable agents.
Clinical limitations of current treatments
Cytotoxic chemotherapy Platinum-based chemotherapy offers symptomatic relief and modest improvements in survival (rarely >2 months) (Breathnach et al., 2001) , for a median survival time of approximately 7-10 months (Kelly et al., 2001; Scagliotti et al., 2002; Schiller et al., 2002) . Several randomized studies have investigated the use of platinum-based regimens that include agents such as paclitaxel and gemcitabine. For example, the ECOG conducted a randomized clinical study comparing four platinum-based two-drug chemotherapy regimens (gemcitabine plus cisplatin, docetaxel plus cisplatin, paclitaxel plus carboplatin and cisplatin plus paclitaxel) in 1155 patients (Schiller et al., 2002) . The median survival time was 7.9 months, with no significant differences in OS among the groups (Schiller et al., 2002) . Although cisplatin plus gemcitabine was associated with a statistically significantly longer time to progression (4.2 months, compared with 3.4 months for the reference arm cisplatin plus paclitaxel; P ¼ 0.001), it was also more likely to cause grade 3-5 renal toxicity (in 9% of patients, compared with 3% of patients receiving cisplatin plus paclitaxel). It was concluded that none of the four chemotherapy regimens studied offered any specific advantage (Schiller et al., 2002) .
The Italian Lung Cancer Project randomly assigned 612 patients with advanced NSCLC to one of three regimens, cisplatin plus vinorelbine, gemcitabine plus cisplatin or paclitaxel plus carboplatin. There were no significant differences in response rate, time to progression or median survival time between the regimens (Scagliotti et al., 2002) . A Japanese trial randomly assigned 602 patients with advanced NSCLC and no earlier chemotherapy to cisplatin plus irinotecan, carboplatin plus paclitaxel, cisplatin plus gemcitabine or cisplatin plus vinorelbine. The four regimens had similar efficacy, as assessed by both response rates and survival (Ohe et al., 2007) .
Clearly, the current nonspecific, nonselective treatment of patients with NSCLC with chemotoxic chemotherapy results in a modest increase in survival at the cost of significant toxicity to the patient; therefore, more effective, less toxic agents are needed (Breathnach et al., 2001; Carney, 2002) .
EGFR TKIs
Although first-generation, reversible EGFR TKIs are promising therapeutic agents for patients with NSCLC, most patients ultimately show resistance to them (Engelman and Ja¨nne, 2008) . Resistance to EGFR inhibitors can be categorized as either primary (affecting patients who are initially refractory to treatment) or acquired (affecting patients who initially respond to treatment but subsequently experience a loss of response).
Multiple mechanisms have been implicated in the resistance to EGFR inhibitors. With regard to primary resistance, certain molecular factors have been identified that are predictive of response, such as increased EGFR gene copy number and activating mutations within the EGFR TK domain (Metro et al., 2006; Riely et al., 2006; Sharma et al., 2007) . Thus, patients without these characteristics are more likely to present with primary resistance to EGFR inhibitors. Several other factors have also been implicated in mediating primary resistance, such as the presence of insertion mutations in exon 20 that precludes the binding of gefitinib and erlotinib to the EGFR TK domain, and thereby confers resistance. Although these mutations typically develop during treatment with EGFR inhibitors, they have been detected before drug exposure and are believed to have a role in primary resistance (Greulich et al., 2005; Shih et al., 2005; Maheswaran et al., 2008) . In addition, mutations in the KRAS oncoprotein, a downstream mediator of EGFR signaling, are significantly associated with primary resistance (Eberhard et al., 2005; Pao et al., 2005; Tsao et al., 2006; Jackman et al., 2007; Massarelli et al., 2007; van Zandwijk et al., 2007) .
Two major underlying mechanisms account for the development of acquired resistance. First, there is the emergence of certain resistance-conferring mutations in the EGFR TK domain. The most common of these mutations involves the substitution of a threonine for methionine at position 790 (T790M) (Kobayashi et al., 2005; Balak et al., 2006; Kosaka et al., 2006) . This mutation has been found in approximately 50% of patients who become resistant to gefitinib and erlotinib (Balak et al., 2006; Kosaka et al., 2006; Engelman et al., 2007) . The second major mechanism of acquired resistance is the amplification of the c-MET protooncogene. Engelman et al. (2007) found that c-MET amplification occurred in 4 (22%) of 18 lung cancer biopsy samples obtained from patients with acquired resistance to gefitinib or erlotinib. They also found that c-MET amplification mediated resistance to EGFR TKIs in a gefitinib-sensitive lung cancer cell line. Given that T790M and c-MET amplification collectively account for approximately 60% of the acquired resistance cases, there are clearly additional mechanisms that underlie resistance to EGFR TKIs. Other mechanisms that have been implicated in acquired resistance include altered EGFR trafficking (Kwak et al., 2005) , expression of insulin-like growth factor-1 (Morgillo et al., 2007) , amplification of mutant EGFR or hyperactivation of components of downstream signaling pathways (Habib et al., 2003) , and expression of the ABCG2 drug-efflux transporter (Elkind et al., 2005) .
Another potential limitation with EGFR inhibitors may be increased toxicity in elderly patients. In a retrospective analysis of patients treated in a randomized, double-blind, placebo-controlled phase III trial of erlotinib, patients aged X70 years were compared with patients aged o70 years. This study showed a significantly greater incidence of severe (grade 3-4) toxicity in the older patients compared with that in the younger patients (35 vs 18%; Po0.001). However, it should be noted that there was no significant difference in PFS between the two populations (Wheatley-Price et al., 2008).
Cetuximab
As discussed above, cetuximab is now recommended by the NCCN as a first-line treatment for advanced NSCLC, although it is not yet approved in this indication. Data from several phase II trials have shown improved response rates in chemotherapy-naive patients receiving platinum-based doublet chemotherapy augmented with cetuximab compared with those receiving chemotherapy alone (Butts et al., 2007; Rosell et al., 2008) . In addition, results from the phase III FLEX trial showed improved OS when cetuximab was added to first-line platinum-based chemotherapy (cisplatin/vinorelbine). However, this improvement was modest, with an increase of only approximately 1 month (11.3 vs 10.1 months; P ¼ 0.0441) (Pirker et al., 2008) . Cetuximab was associated with an increased rate of grade 3/4 febrile neutropenia (22 vs 15%; Po0.05) (Pirker et al., 2008) . Treatment with cetuximab is limited to only patients with advanced NSCLC who meet specific criteria, which includes patients with EGFR-positive tumors (X1 positive tumor cell), aged X18 years, ECOG PS of 0-2, no brain metastases, and no earlier chemotherapy or EGFR-targeted therapy.
Bevacizumab
One of the key limitations of bevacizumab therapy is that it is restricted to use in only certain subpopulations of patients with NSCLC. Bevacizumab is associated with bleeding-related adverse events, particularly among patients with squamous cell histology (Johnson et al., 2004) . As a result, bevacizumab is not indicated for the treatment of patients with squamous cell NSCLC (Avastin PI, 2008). In addition, owing to the risk of bleeding-related adverse events, patients with central nervous system metastases, a history of hemoptysis or ongoing anticoagulation therapy are not eligible to receive bevacizumab (Sandler et al., 2006; NCCN, 2008) . Patients who do not meet the criteria for bevacizumab represent a substantial proportion of the overall NSCLC patient population (Gridelli et al., 2007) . It is noted that, in the phase III ECOG-4599 trial, 15 treatment-related deaths occurred with bevacizumab plus carboplatin/paclitaxel (five due to pulmonary hemorrhage, five due to febrile neutropenia, two due to a cerebrovascular event or gastrointestinal hemorrhage, and one due to a probable pulmonary embolus). These events occurred despite the exclusion of patients with squamous histology, brain metastases or a history of hemoptysis (Sandler et al., 2006) . Other adverse events commonly associated with bevacizumab include hypertension, proteinuria, bleeding, neutropenia, febrile neutropenia, thrombocytopenia, hyponatremia, rash and headache (Sandler et al., 2006) .
Agents in clinical development
Several new therapies are in clinical development for the treatment of patients with NSCLC (Table 1) . Among the agents in development are the dual, irreversible EGFR/HER2 TKIs, antiangiogenic therapies and dual EGFR/VEGF inhibitors.
Dual EGFR/HER2 irreversible inhibitors
A new generation of dual irreversible inhibitors of EGFR and HER2 is under development. Several irreversible inhibitors have shown preclinical activity against EGFR mutations that are resistant to reversible EGFR TKIs (that is, gefitinib and erlotinib). Studies have also shown that resistance develops less frequently with irreversible EGFR TKIs than with reversible inhibitors (Kwak et al., 2005) . Moreover, the dual EGFR/HER2 inhibition interrupts the cooperative signaling between EGFR and HER2, which could potentially lead to improved efficacy (Britten, 2004) . Indeed, early preclinical studies have shown that the inhibition of more than one member of the EGFR family yields improved antitumor activity compared with targeting a single receptor (Ye et al., 1999) . From the available clinical data, this class of agents seems to be generally safe and well tolerated in patients with NSCLC. Several irreversible EGFR/HER2 inhibitors are in various phases of clinical development (Table 1) . The most clinically advanced agents include BIBW 2992 and neratinib .
BIBW 2992 is a novel, orally bioavailable dual irreversible inhibitor of EGFR and HER2. In a phase I study, the most common adverse events observed included mild gastrointestinal events (diarrhea and vomiting) and cutaneous events (dry skin, folliculitis and skin rash). Elevations in transaminase and alkaline phosphatase levels were also observed. Importantly, all adverse events were reversible (Eskens et al., 2008) . A phase II study is currently under way to evaluate patients with advanced lung adenocarcinoma who harbor activating EGFR mutations after earlier chemotherapy. Preliminary results from this study have shown efficacy, with partial responses achieved in five of six evaluable patients and stable disease reported in one of six evaluable patients (Yang et al., 2008) . In addition, a phase III randomized study is now under way to evaluate BIBW 2992 vs best supportive care in patients with NSCLC after the failure of erlotinib or gefitinib.
Neratinib (HKI-272) is another dual irreversible inhibitor of EGFR and HER2. A phase I doseescalating study in patients with solid tumors, included 12 evaluable patients with NSCLC, showed no confirmed responses, but five patients who had progressed on erlotinib or gefitinib achieved stable disease for >24 weeks. The most common treatment-related grade 1 through 3 adverse events were diarrhea, nausea and asthenia (Wissner and Mansour, 2008) .
Antiangiogenic agents
A number of novel antiangiogenic agents are being investigated for the treatment of advanced NSCLC (Table 1) , including several TKIs. Sunitinib is a TKI with activity against VEGF receptor (VEGFR)-1, -2 and -3; platelet-derived growth factor receptor and other TKs (Flt-3 and c-Kit) (Abrams et al., 2003) . An initial phase II trial in 63 previously treated patients with NSCLC using an intermittent-dose schedule showed a response rate of 11.1% and a stable disease rate of 28.6%. The median PFS and OS were 12.0 and 23.4 weeks, respectively . The principal toxicities included fatigue, pain, myalgia, nausea and vomiting. Grade 3 hypertension was also reported in 5% of the patients. Three hemorrhage-related deaths were reported (two pulmonary and one central nervous system related) . Sunitinib is currently being evaluated in combination with a number of standard regimens commonly used in NSCLC and as a maintenance drug after the first-line platinum-based treatment of patients with advanced NSCLC.
Sorafenib is a TKI with activity against VEGFR-2 and -3, and platelet-derived growth factor receptor; however, unlike sunitinib, it also inhibits the Raf oncoprotein. Results from phase II trials indicated that this agent has activity in NSCLC. In a phase II study of sorafenib in patients with relapsed or refractory advanced NSCLC, no objective responses were reported; however, the rate of stable disease was 59%. The most commonly reported adverse events were diarrhea, hand-foot syndrome, fatigue and nausea. Grade 3-4 hypertension was also reported in 4% of the patients (Gatzemeier et al., 2006) . Results from a planned interim analysis of a large phase III trial (n ¼ 926) of sorafenib plus chemotherapy (carboplatin/ paclitaxel) in patients with NSCLC showed no benefit. In fact, in a small subset of patients with squamous cell histology, the addition of sorafenib seemed to have a detrimental effect, leading to an increased risk of mortality. As a result, the trial was stopped prematurely. Median OS was similar between the two treatment groups (10.7 months with carboplatin/paclitaxel/sorafenib and 10.6 months with carboplatin/paclitaxel alone). However, in the subset of patients with squamous cell histology (n ¼ 219; 24%), there was greater mortality in the sorafenib group than in the placebo group (Scagliotti et al., 2008b) . A number of other trials with sorafenib are ongoing, including one in which sorafenib is added to a combination of cisplatin and gemcitabine. BIBF 1120 is a novel, oral antiangiogenic TKI with activity against three pro-angiogenesis receptors, VEGFR (-1, -2 and -3), platelet-derived growth factor receptor (a and b) and fibroblast growth factor receptor (-1, -2 and -3) (Hilberg et al., 2008) . Preliminary results from a randomized phase II study comparing two dosing schedules of BIBF 1120 (150 and 250 mg BID) in patients with previously treated NSCLC showed similar results between the two arms, with a stable disease rate of 48% and a median PFS of 2.9 months. The outcomes seemed slightly improved in patients with a PS of 0 or 1 compared with those in patients who had a PS of 2 (Von Pawel et al., 2007) . Major toxicities associated with single-agent BIBF 1120 are nausea, vomiting and diarrhea. Interestingly, this agent is not associated with hypertension or hand-foot syndrome, both of which are common with other antiangiogenic agents (Mross et al., 2005; Von Pawel et al., 2007) .
Dual EGFR/VEGFR inhibitors
The inhibition of both EGFR and VEGFR signaling pathways may be more effective than the inhibition of a single pathway. Therapeutics targeting combined inhibition may improve antitumor efficacy and overcome resistance to EGFR inhibition (Tabernero, 2007) . Therefore, a number of oral TKIs that target both EGFR and VEGFR are in development (Table 1) , of which vandetanib and XL647 are the most clinically advanced.
Vandetanib (ZD6474) targets EGFR and VEGFR, and has additional activity against the RET receptor TK. A randomized phase II study evaluated vandetanib and gefitinib in the second-and third-line treatment of patients with advanced NSCLC. Median PFS was significantly longer with vandetanib than with gefitinib (11.0 vs 8.1 weeks; P ¼ 0.011); however, OS did not differ significantly between the two groups. The most prominent adverse events associated with vandetanib were diarrhea and rash (Natale et al., 2006) . Another phase II study compared the combination of vandetanib and chemotherapy (carboplatin/paclitaxel) against chemotherapy alone in patients with previously untreated NSCLC. The results of this study showed that vandetanib prolonged PFS compared with chemotherapy alone (24 vs 23 weeks). Furthermore, this combination was shown to be tolerable. Rates of severe hypertension were low, and no cases of hemoptysis were reported (Heymach et al., 2007) . Vandetanib is currently being investigated in several phase III studies in patients with advanced NSCLC.
XL647 is a reversible inhibitor of multiple receptor TKs, including EGFR, HER2 and VEGFR2 (Gendreau et al., 2007; Rizvi et al., 2007) . This agent is being evaluated in an ongoing phase II trial in patients who progressed after earlier benefit from erlotinib or gefitinib, or who had a documented T790M mutation. Preliminary results from this study showed that 20 (51%) of 39 evaluable patients experienced disease control (partial response (n ¼ 1) or stable disease (n ¼ 19)) in response to treatment with XL647. A total of 10 patients were found to harbor T790M mutations, 3 of whom achieved stable disease. XL647 was generally well tolerated in this patient population, with diarrhea, fatigue and rash being the most common adverse events (Miller et al., 2008) .
Other agents
Overexpression of the anti-apoptosis protein BCL-2 has been observed in numerous tumor types (Adams and Cory, 2007) and is associated with an increased resistance to chemotherapy (Campos et al., 1993; Dole et al., 1994) . Oblimersen is an antisense oligonucleotide targeted against the BCL-2 mRNA. In a variety of xenograft tumor models, oblimersen augmented the efficacy of chemotherapy (Herbst and Frankel, 2004) . However, results from a phase II trial in patients with previously treated NSCLC showed no improvement in OS with oblimersen and docetaxel compared with docetaxel alone (Herbst et al., 2007) .
Several attempts have also been made to use vaccines and immunotherapies in the treatment of patients with NSCLC; however, the efficacy of such agents has been mostly disappointing (O'Brien et al., 2004; Morse et al., 2005; Nemunaitis et al., 2006; Bolonaki et al., 2007; Manegold et al., 2008) . Recently reported results from a randomized phase II trial of patients with advanced NSCLC indicate that the addition of the toll-like receptor-9 agonist PF-3512676 to standard first-line chemotherapy (a taxane plus a platinum-based compound) improved the objective response rate over that achieved with chemotherapy alone (38 vs 19%; P ¼ 0.043). OS also seemed to be improved, with a median of 12.3 months in the patients receiving PF-3512676 and 6.8 months in the patients receiving chemotherapy alone (Manegold et al., 2008) . Phase III trials of this agent in patients with NSCLC are ongoing. In addition, several other immunotherapies and vaccines are being evaluated in patients with NSCLC.
Histone deacetylase is a key modulator of the expression of several genes involved in cellular proliferation and survival. The inhibition of histone deacetylase activity has been shown to induce growth arrest and cell death in numerous tumor cell lines (Marks et al., 2000) . A number of histone deacetylase inhibitors are under development for NSCLC, including vorinostat, LBH-589, PDX-101 and MS-275.
Clinical potential of new agents
In addition to the classes of agents discussed above, several others are in development for NSCLC (Table 1) . Collectively, these new agents offer hope for more diverse and better treatment options with improved efficacy and safety profiles compared with the currently available treatments. Given the significant issue of resistance, second-generation agents may be effective in patients who are resistant to the first generation of a specific class of agents (that is, irreversible EGFR inhibitors may overcome resistance to gefitinib/erlotinib). In addition, resistance to one class of agents could be overcome by using agents of another class; for example, histone deacetylase inhibitors may be effective in patients with resistance to EGFR inhibitors (Haber and Settleman, 2005) . Overall, the primary goal with any treatment is to achieve lasting response. Thus, compared with existing treatments, the goal with newer agents is to achieve more durable response and to reduce the likelihood of resistance.
Conclusion
Despite many advances, there are still significant limitations in the treatment options for patients with advanced disease. Unmet medical needs exist for agents that enhance OS and PFS, yield durable responses, show clinical activity in resistant patient populations, and have better safety and tolerability profiles than do current agents. Several novel agents are in development that may hold promise for providing improved clinical benefits with better safety and tolerability.
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